Anacetrapib, but not evacetrapib, in spite of marked HDL-C increase impairs endothelial function in CETP-transgenic mice

•CETP inhibitors, anacetrapib and evacetrapib, increased HDL-C and reduced triglyceride levels in hyperlipidemic mice.•Anacetrapib reduced cholesterol levels while evacetrapib increased cholesterol efflux and PON-1 activity and reduced ROS.•Anacetrapib worsen endothelium-dependent acetylcholine-induced vasorelaxation while evacetrapib showed no effect.•CETP inhibition lacks vascular protective effects and compromised vascular function may lead to more cardiovascular events.